Avivagen Inc. Stock

Equities

VIV

CA05382F2026

Fishing & Farming

Delayed Toronto S.E. 09:30:00 2024-03-05 am EST 5-day change 1st Jan Change
0.005 CAD -.--% Intraday chart for Avivagen Inc. -.--% -.--%
Sales 2021 1.3M 947K Sales 2022 939K 687K Capitalization 10.42M 7.62M
Net income 2021 -6M -4.39M Net income 2022 -6M -4.39M EV / Sales 2021 21.5 x
Net Debt 2021 5.4M 3.95M Net Debt 2022 5.8M 4.24M EV / Sales 2022 17.3 x
P/E ratio 2021
-3.24 x
P/E ratio 2022
-1.47 x
Employees 13
Yield 2021 *
-
Yield 2022
-
Free-Float 98.89%
More Fundamentals * Assessed data
Dynamic Chart
Current year
0.01
Extreme 0.005
0.01
1 year
0.01
Extreme 0.005
0.03
3 years
0.01
Extreme 0.005
0.58
5 years
0.00
Extreme 0
0.84
10 years
0.00
Extreme 0
2.15
More quotes
Managers TitleAgeSince
Founder - 05-08-03
Chief Executive Officer 68 14-04-03
Director of Finance/CFO - -
Members of the board TitleAgeSince
Chairman 59 13-11-30
Director/Board Member - 17-11-21
Chief Executive Officer 68 14-04-03
More insiders
Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.
More about the company